Condition: Diffuse Large B Cell Lymphoma (DLBCL) · Sponsor: Sun Yat-sen University
This is a prospective, single-arm, multicenter, phase II clinical trial to evaluate the efficacy and safety of orelabrutinib combined with the R-CHOP (rituximab, cyclophosphamide, vincristine, doxorubicin, and prednisone) regimen as first-line treatment in CD5-positive diffuse large B-cell lymphoma (DLBCL) patients.
This description comes directly from the study's public registry record.
Qingqing Cai, MD. PhD. · 02087342823 · caiqq@sysucc.org.cn
Yi Xia, MD. PhD. · 02087342823 · xiayi@sysucc.org.cn
Always discuss trial participation with your own doctor first.
| Sun Yat-sen Universitiy Cancer Center, Sun Yat-Sen University, | Guangzhou, China, China | Recruiting |
| Gansu Cancer Hospital | Lanzhou, Gansu, China | Recruiting |
| Dongguan People's Hospital | Dongguan, Guangdong, China | Recruiting |
| Fifth Affiliated Hospital of Guangzhou Medical University | Guangzhou, Guangdong, China | Recruiting |
| First People's Hospital of Guangzhou | Guangzhou, Guangdong, China | Recruiting |
| Guangdong Provincial Hospital of Traditional Chinese Medicine | Guangzhou, Guangdong, China | Recruiting |
| Second Affiliated Hospital of Guangzhou Medical University | Guangzhou, Guangdong, China | Recruiting |
| First Affiliated Hospital of Shantou University Medical College. | Shantou, Guangdong, China | Recruiting |
| Shenzhen People's Hospital | Shenzhen, Guangdong, China | Recruiting |
| Zhaoqing First People's Hospital | Zhaoqing, Guangdong, China | Recruiting |
| Fifth Affiliated Hospital of Sun Yat-sen University | Zhuhai, Guangdong, China | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06647940